PMID- 31158747 OWN - NLM STAT- Publisher LR - 20190606 IS - 1768-3254 (Electronic) IS - 0223-5234 (Linking) VI - 177 DP - 2019 May 17 TI - C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays. PG - 316-337 LID - S0223-5234(19)30451-9 [pii] LID - 10.1016/j.ejmech.2019.05.041 [doi] AB - Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these residue differences between the histone substrate binding sites in order to improve affinity for the KDM4-subfamily over KDM5-subfamily enzymes. In particular, residues E169 and V313 (KDM4A numbering) were targeted. Additionally, conformational restriction of the flexible pyridopyrimidinone C8-substituent was investigated. These approaches yielded potent and cell-penetrant dual KDM4/5-subfamily inhibitors including 19a (KDM4A and KDM5B Ki=0.004 and 0.007muM, respectively). Compound cellular profiling in two orthogonal target engagement assays revealed a significant reduction from biochemical to cell-based activity across multiple analogues; this decrease was shown to be consistent with 2OG competition, and suggests that sub-nanomolar biochemical potency will be required with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve sub-micromolar target inhibition in cells. CI - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Le Bihan, Yann-Vai AU - Le Bihan YV AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Lanigan, Rachel M AU - Lanigan RM AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Atrash, Butrus AU - Atrash B AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - McLaughlin, Mark G AU - McLaughlin MG AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Velupillai, Srikannathasan AU - Velupillai S AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK. FAU - Malcolm, Andrew G AU - Malcolm AG AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - England, Katherine S AU - England KS AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK. FAU - Ruda, Gian Filippo AU - Ruda GF AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK. FAU - Mok, N Yi AU - Mok NY AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Tumber, Anthony AU - Tumber A AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK. FAU - Tomlin, Kathy AU - Tomlin K AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Saville, Harry AU - Saville H AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Shehu, Erald AU - Shehu E AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - McAndrew, Craig AU - McAndrew C AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Carmichael, LeAnne AU - Carmichael L AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Bennett, James M AU - Bennett JM AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK. FAU - Jeganathan, Fiona AU - Jeganathan F AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Eve, Paul AU - Eve P AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Donovan, Adam AU - Donovan A AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Hayes, Angela AU - Hayes A AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Wood, Francesca AU - Wood F AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Raynaud, Florence I AU - Raynaud FI AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Fedorov, Oleg AU - Fedorov O AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK. FAU - Brennan, Paul E AU - Brennan PE AD - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK. FAU - Burke, Rosemary AU - Burke R AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - van Montfort, Rob L M AU - van Montfort RLM AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Rossanese, Olivia W AU - Rossanese OW AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. FAU - Blagg, Julian AU - Blagg J AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. Electronic address: julian.blagg@icr.ac.uk. FAU - Bavetsias, Vassilios AU - Bavetsias V AD - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK. Electronic address: vassilios.bavetsias@icr.ac.uk. LA - eng PT - Journal Article DEP - 20190517 PL - France TA - Eur J Med Chem JT - European journal of medicinal chemistry JID - 0420510 OTO - NOTNLM OT - Histone demethylases OT - KDM inhibitors OT - KDM4 subfamily OT - KDM5 subfamily OT - Pyridopyrimidinones EDAT- 2019/06/04 06:00 MHDA- 2019/06/04 06:00 CRDT- 2019/06/04 06:00 PHST- 2019/01/04 00:00 [received] PHST- 2019/05/14 00:00 [revised] PHST- 2019/05/14 00:00 [accepted] PHST- 2019/06/04 06:00 [pubmed] PHST- 2019/06/04 06:00 [medline] PHST- 2019/06/04 06:00 [entrez] AID - S0223-5234(19)30451-9 [pii] AID - 10.1016/j.ejmech.2019.05.041 [doi] PST - aheadofprint SO - Eur J Med Chem. 2019 May 17;177:316-337. doi: 10.1016/j.ejmech.2019.05.041.